3-((+/-)-2-CARBOXYPIPERAZIN-4-YL)PROPYL-1-PHOSPHONIC ACID (CPP) AND PHENCYCLIDINE PRODUCE A DEFICIT OF PASSIVE-AVOIDANCE RETENTION IN RATS

被引:35
作者
DENOBLE, VJ
JONES, KW
SCHAEFFER, CL
BAUERLE, LM
机构
[1] E.I. du Pont de Nemours, Co., Inc., Medical Products Department, Wilmington, DE 19880-0400
关键词
Benzodiazepines; CCP (3-((±)-2-carboxupiperazin-4-yl)-propyl-1-phosphonic acid); Passive avoidance deficit; Phencyclidine; Ro; 15-1788;
D O I
10.1016/0014-2999(90)90230-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
3-((±)-2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CCP), phencyclidine (PCP) and diazepam were evaluated for their ability to produce a deficit for a single trial step-through passive avoidance response in rats. Pretraining administration with CCP at doses ranging from 2.0 to 10.0 mg/kg s.c. significantly decreased retention latencies 24 h after passive avoidance training. Similar effects were found with PCP at doses ranging from 0.5 to 1.7 mg/kg s.c. and diazepam at doses between 5.0-18.0 mg/kg s.c. Pretraining administration with the benzodiazepine antagonist, RO15-1788 at doses between 0.1-15 mg/kg s.c., did not alter retention latencies. Co-administration of RO15-1788 (0.01-15.0 mg/kg s.c.) with CCP (6.0 mg/kg s.c.) or PCP (1.0 mg/kg s.c.) failed to block decreases in latencies. However, when RO15-1788 was co-administered with diazepam (9.0 mg/kg s.c.) a dose-related antagonism of diazepam's effects were found. These results suggest that the behavioral actions of CCP and PCP on passive avoidance retention are not mediated via the benzodiazepine receptor complex. © 1990.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 29 条
[1]   THE DISSOCIATIVE ANESTHETICS, KETAMINE AND PHENCYCLIDINE, SELECTIVELY REDUCE EXCITATION OF CENTRAL MAMMALIAN NEURONS BY N-METHYL-ASPARTATE [J].
ANIS, NA ;
BERRY, SC ;
BURTON, NR ;
LODGE, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (02) :565-575
[2]  
BENNETT DA, 1987, EXCITATORY AMINO ACI, P213
[3]   EPISODIC LONG-TERM-MEMORY IN THE RAT - EFFECTS OF HIPPOCAMPAL-STIMULATION [J].
BIERLEY, RA ;
KESNER, RP ;
NOVAK, JM .
BEHAVIORAL NEUROSCIENCE, 1983, 97 (01) :42-48
[4]  
BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274
[5]   BENZODIAZEPINE ANTAGONIST RO 15-1788 - NEUROLOGICAL AND BEHAVIORAL-EFFECTS [J].
BONETTI, EP ;
PIERI, L ;
CUMIN, R ;
SCHAFFNER, R ;
PIERI, M ;
GAMZU, ER ;
MULLER, RKM ;
HAEFELY, W .
PSYCHOPHARMACOLOGY, 1982, 78 (01) :8-18
[6]  
DANYSZ E, 1988, FASEB J, V2, pA311
[7]   CPP, A NEW POTENT AND SELECTIVE NMDA ANTAGONIST - DEPRESSION OF CENTRAL NEURON RESPONSES, AFFINITY FOR [H-3] D-AP5 BINDING-SITES ON BRAIN MEMBRANES AND ANTICONVULSANT ACTIVITY [J].
DAVIES, J ;
EVANS, RH ;
HERRLING, PL ;
JONES, AW ;
OLVERMAN, HJ ;
POOK, P ;
WATKINS, JC .
BRAIN RESEARCH, 1986, 382 (01) :169-173
[8]  
DAVIS J L, 1987, Society for Neuroscience Abstracts, V13, P658
[9]  
DENOBLE VJ, 1988, EUROPEAN BEHAV PHARM, V2, P13
[10]   DENSITY AND DISTRIBUTION OF NMDA RECEPTORS IN THE HUMAN HIPPOCAMPUS IN ALZHEIMERS-DISEASE [J].
GEDDES, JW ;
CHANGCHUI, H ;
COOPER, SM ;
LOTT, IT ;
COTMAN, CW .
BRAIN RESEARCH, 1986, 399 (01) :156-161